Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program

Cytotherapy

Volumn 11, Issue 7, 2009, Pages 923-935

  Powell Jr , Daniel J ^a   Brennan, Andrea L ^a,b   Zheng, Zhaohui ^a,b   Huynh, Hong ^a,b   Cotte, Julio ^a,b   Levine, Bruce L ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cell separation; Elutriation; Immunotherapy; Leukapheresis; Monocytes; T cells

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CELL SEPARATION; CELL SIZE; COMPUTER PROGRAM; COULTER COUNTER; COUNTER FLOW CENTRIFUGAL ELUTRIATION TECHNIQUE; DONOR; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKAPHERESIS; LYMPHOCYTE; LYMPHOCYTE DEPLETION; MONOCYTE; NEOPLASM; PRIORITY JOURNAL; SEPARATION TECHNIQUE;

EID: 70450180829     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653240903188921     Document Type: Article

References (63)

1. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: Building on success. Nat Rev Immunol 2006;6:383-393
2. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007;117:1204-1212
3. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117:1466-1476
4. Levine BL. T lymphocyte engineering ex vivo for cancer and infectious disease. Expert Opin Biol Ther 2008;8:475-489
5. +-selected hematopoietic cell transplantation. Blood 2003;102:2004-2013
6. + T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother 1998;7:437-448
7. Rapoport AP, Levine BL,Badros A,Meisenberg B,Ruehle K, Nandi A, et al. Molecular remission of CML after autotrans-plantation followed by adoptive transfer of costimulated autologous T cells. Bone Marrow Transplant 2004;33:53-60.
8. Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005;11:1230-1237
9. Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006;107:1325-1331
10. Powell DJ Jr, de Vries CR, Allen T, Ahmadzadeh M, Rosenberg SA. Inability to mediate prolonged reduction of regulatory T cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy. J Immunother 2007;30:438-447
11. Thistlethwaite FC, Elkord E, Griffiths RW, Burt DJ, Shablak AM, Campbell JD, et al. Adoptive transfer ofT(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol Immunother 2008;57:623--34.
12. + T cells against NY-ESO-1. N Engl J Med 2008;358:2698-2703
13. +T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006;24:5060-5069
14. Powell DJ Jr, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 2006;177:6527-6539
15. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-129
16. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006; 103:17372-17377
17. Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000;96:467-474
18. Ino K,Ageitos AG, Singh RK,TalmadgeJE. Activation-induced T cell apoptosis by monocytes from stem cell products, hit Immunopharmacol 2001;1:1307-1319
19. + T cells through a COX-2-PGE2-dependent mechanism, hit Immunol 2008;20:235-245.
20. BergerTG, Strasser E, Smith R, Carste C, Schuler-Thurner B, Kaempgen E, Schuler G. Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells. J Immunol Methods 2005;298:61-72.
21. Elias M, van Zanten J, Hospers GA, Setroikromo A, de Jong MA, de Leij LF, Mulder NH. Closed system generation of dendritic cells from a single blood volume for clinical application in immunotherapy. J ClinApher 2005; 20:197-207.
22. Erdmann M, Dorrie J, Schaft N, Strasser E, Hendelmeier M, Kampgen E, etal. Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection. J Immunother 2007;30:663-674
23. Gulen D, Abe F, Maas S, Reed E, Cowan K, Pirruccello S, Wisecarver J, et al. Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors. Int Immunopharmacol 2008;8:1728-1736
24. Jarnjak-Jankovic S, Hammerstad H, Saeboe-Larssen S, Kvalheim G, Gaudernack G. A full scale comparative study of methods for generation of functional dendritic cells for use as cancer vaccines. BMC Cancer 2007;7:119.
25. Kim S, Kim HO, Baek EJ, Choi Y, Kim HS, Lee MG. Monocyte enrichment from leukapheresis products by using the Elutra cell separator. Transfusion 2007;47:2290-2296
26. Lemarie C, Sugaye R, Kaur I, Taga T, Chabannon C, Schuyler R, McMannis J. Purification of monocytes from cryopreserved mobilized apheresis products by elutriation with the Elutra device. J Immunol Methods 2007;318:30-36
27. Perseghin P, D'Amico G, Dander E, Gaipa G, Dassi M, Biagi E, Biondi A. Isolation of monocytes from leukapheretic products for large-scale GMP-grade generation of cytomegalovirus-specific T-cell lines by means of an automated elutriation device. Transfusion 2008;48:1644-1649
28. Pullarkat V, Lau R, Lee SM, Bender JG, Weber JS. Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells. J Immunol Methods 2002;267:173-183
29. Rouard H, Leon A, De Reys S, Taylor L, Logan J, Marquet J, et al. A closed and single-use system for monocyte enrichment: Potential for dendritic cell generation for clinical applications. Transfusion 2003;43:481-487
30. Sorg RV, Ozcan Z, Brefort T, Fischer J, Ackermann R,Muller M, Wernet P. Clinical-scale generation of dendritic cells in a closed system. J Immunother 2003 ;26:3 74-83.
31. Wong EC, Maher VE, Hines K, Lee J, Carter CS, Goletz T, et al. Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. Cytotherapy 2001;3:19-29.
32. + monocytes to generate dendritic cells for cancer immunotherapy: A phase I study. J Hematother Stem Cell Res 2003;12:515-523
33. Chen Y, Hoecker P, Zeng J, Dettke M. Combination of Cobe AutoPBSC and Gambro Elutra as a platform for monocyte enrichment in dendritic cell (DC) therapy: Clinical study. J ClinApher 2008;23:157-162
34. Faradji A, Bohbot A, Schmitt-Goguel M, Dumont S, Eischen A, Wiesel ML, et al. Apheresis-elutriation program for adoptive immunotherapy with autologous activated monocytes in cancer patients. Int J Artif Organs 1991;14:304-312
35. Whiteside TL, Piazza P, Reiter A, Stanson J, Connolly NC, Rinaldo CR Jr, Riddler SA. Production of DC-based vaccine containing inactivated autologous virus for therapy of patients with chronic HIV-1 infection. Clin Vaccine Immunol 2009;16:233-240
36. Berger CL, Edelson RL. Comparison of lymphocyte function after isolation by ficoll-hypaque flotation or elutriation. J Invest Dermatol 1979;73:23 1-5.
37. Tuyaerts S, Noppe SM, Cordials J, Breckpot K, Heirman C, De Greef C, et al. Generation of large numbers of dendritic cells in a closed system using Cell factories. J Immunol Methods 2002;264:135-151
38. Chabannon C, Novakovitch G, Blache JL, Olivero S, Camerlo J, Genre D, et al. The role of autologous hematopoietic progenitor and cell reinfusion for intensive chemotherapy in women with poor-prognosis breast cancer. Clinical studies with ex-vivo expanded cells produced with the Aastrom Rep-licell technology. Hematol Cell Ther 1999;41:78-81.
39. Jaroscak J, Goltry K, Smith A, Waters-Pick B, Martin PL, Driscoll TA, et al. Augmentation of umbilical cord blood (UCB) transplantation with ex two-expanded UCB cells: Results of a phase 1 trial using the AastromReplicell system. Blood 2003;101:5061-5067
40. Thompson JA, Figlin RA, Sifri-Steele C, Berenson RJ, Frohlich MW A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin Cancer Res 2003;9:3562-3570
41. + monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. Br J Haematol 2003; 121:240-250
42. + precursors: Experience from phase I clinical trials in CML and malignant melanoma. Cytotherapy 2004;6:563-570
43. Barfield RC, Otto M, Houston J, Holladay M, Geiger T, Martin J, et al. A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy 2004;6:1-6.
44. Humeau L, Cohen R, Encinas T, Skripchenko Y, Lemiale F, Andre K, et al. Design and implementation of VRX496 phase II cell processing for cGMP production of multiple doses of lentivirally transduced autologous HIV infected CD4 + T lymphocytes. Molecular Therapy 2006;S427.
45. Peters JH, Preijers FW, Woestenenk R, Hilbrands LB, Koenen HJ, Joosten I. Clinical grade Treg: GMP isolation, improvement of purity by CD 127 depletion, Treg expansion, and Treg cryopreservation. PLoS ONE 2008;3:e3161.
46. Powell DJ Jr, Parker LL, Rosenberg SA. Large-scale depletion of CD25+ regulatory T cells from patient leuka-pheresis samples. JImmunother 2005;28:403-411
47. high reguiatory T cells from leukapheresis products from ulcerative colitis patients, applicable to regulatory T-cell transfer therapy. Cytotherapy 2008;10:698-710.
48. + regulatory T cells with potent suppressor activity. J Immunol Methods 2006;315:27-36.
49. Bank I, Chess L. Perturbation of the T4 molecule transmits a negative signal to T cells. J Exp Med 1985;162:1294-1303
50. + T cells. J Immunol Methods 2002;271:99-106.
51. + T cells. Proc Natl Acad Sci USA 1996;93:11014-11018
52. Harding S, Lipp P, Alexander DR. A therapeutic CD4 monoclonal antibody inhibits TCR-zeta chain phosphorylation, zeta-associated protein of 70-kDa Tyr319 phosphorylation, and TCR internalization in primary human T cells. J Immunol 2002;169:230-238
53. Haughn L, Gratton S, Caron L, Sekaly RP, Veillette A, Julius M. Association of tyrosine kinase p561ck with CD4 inhibits the induction of growth through the alpha beta T-cell receptor. Nature 1992;358:328-331
54. Jabado N, Pallier A, Le Deist F, Bernard F, Fischer A, Hivroz C. CD4 ligands inhibit the formation of multifunctional transduction complexes involved in T cell activation. J Immunol 1997;158:94-103.
55. Newell MK, Haughn LJ, Maroun CR, Julius MH. Death of mature T cells by separate ligation of CD4 and the T-cell receptor for antigen. Nature 1990;347:286-289
56. Robinet E, Fournel S, Fatmi A, Revillard JR IL-2-resistant hyporesponsiveness induced by CD4 mAbs in OKT3-activated human T cells is reversed by CD45RA triggering. Cell Immunol 1996;167:1-7.
57. Woods M, Guy R, Waldmann H, Glennie M, Alexander DR. A humanised therapeutic CD4 mAb inhibits TCR-induced IL-2, IL-4, and IL-10 secretion and expression of CD25, CD40L, and CD69. Celllmmunol 1998;185:101-113
58. + T cells: Importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol 2006; 176:7726-35.
59. + tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005;105:241-250
60. Shen X, Zhou J, Hathcock KS, Robbins P, Powell DJ Jr, Rosenberg SA, Hodes RJ. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother 2007;30:123-129
61. Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 2005;28:53-62.
62. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 2005; 175:7046-7052
63. + T cells in the absence of exogenous feeder cells. J Immunol 1997; 159:5921-5930